View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, July 15 (HealthDay News) -- Bristol-Myers Squibb has initiated a voluntary recall of physician sample blister packs and hospital unit dose (HUD) blister packs of Coumadin, a medication used to treat or prevent blood clots.
The company determined that, over time, some tablets may lose specifications for isopropanol, an ingredient that keeps the medication's active ingredient in a crystalline state, which could have an effect on its therapeutic properties. A decrease in the active ingredient could raise the risk of blood clots, possibly leading to heart attack and stroke, whereas an increase in the active ingredient raises the risk of bleeding.
Only U.S.-distributed Coumadin 1 mg tablets in blister packs -- not in bottles, or other strengths or dosage forms -- are involved in the recall. The recall includes the following lot numbers for physician sample packs: 9A48931A, 9A48931B, 9A48931C, expiring January 2012; and for HUD blister packs: 8F34006B, 8K44272A, 8K46168A, 9F44437A, and 9K58012B, expiring June 2011 to November 2012.
According to the company's physician-notification letter, the "medical assessment of this situation indicates that there does not appear to be a clinically important risk related to Coumadin 1 mg tablets in regard to isopropanol level. However, use of tablets with low isopropanol could, in some cases, potentially lead to patient-to-patient variation in bioavailability. All other product characteristics, including warfarin sodium assay, are within specification."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top